United States Generic Drugs Market, By Type, By Application, By Mode of Drug Delivery, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast and Opportunity, 2026 – Yahoo Finance

United States Generic Drugs Market, By Type (Small Molecule Generics v/s Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Infectious Diseases, Others), By Mode of Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House v/s Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition, Forecast and Opportunity, 2026
New York, Dec. 23, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "United States Generic Drugs Market, By Type, By Application, By Mode of Drug Delivery, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast and Opportunity, 2026" – https://www.reportlinker.com/p06192577/?utm_source=GNW

United States generic drugs market was valued USD70.78 billion in 2020 and is forecast to grow at CAGR of 9.43% during the forecast period and may achieve market value of USD126.74 billion by the year 2026. Factors like cost effective nature of generic drugs and increasing demand from the developing economies are majorly responsible for this futuristic growth estimation of the United States generic drugs market in the upcoming five years. Generic drugs do not require extensive research and development as in case of prescription drugs and patented drugs. Market players and research institutes invest heavily on patent pharmaceuticals. Also, FDA approvals for the generic drugs are not required since generic drugs contain same composition as that of previously patented drug and thus supports the growth of the United States generic drugs market in the next five years. United States healthcare industry, in terms of the generic drugs, has grown from registering 80% growth in 2020 from previous growth of 20% in 2015.
Increased export of generic drugs to the developing economies like Kenya, India, etc. is also substantiating the growth of the United States generic drugs market in the future five years.
The United States generic drugs market is segmented based on type, mode of drug delivery, form, source of manufacturing, application, company and regional distribution.Based on type, the market can be split into small molecule generics and biosimilars.

Small molecule generics are anticipated to register largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of its simpler and easier manufacturing processes.Generic drug manufacturers during the production of small molecule generics are required to prove that the final product contains identical chemical compounds as that of the patent drug.

With similar pharmacokinetic functions and properties, the small molecule generic is accepted. Moreover, the demand for the cost-effective generic drugs is anticipated to further support the growth of the United States generic drugs market in the future five years.
Based on application, the market can be fragmented into cardiovascular diseases, diabetes, neurology, oncology, infectious diseases, and others.Cardiovascular diseases are expected to dominate the market segment while registering largest revenue shares of the market in the upcoming five years on the account of increasing instances of cardiovascular diseases in the United States.

Moreover, increased demand for the treatment and prolonged medication protocols drives the growth of the sub-segment cardiovascular diseases meanwhile supporting the growth of the Untied States generic drugs market in the next five years. Increasing researches and pharmaceutical developments for the oncology disease is anticipated to drive the growth of the oncology sub-segment and drive the growth of the United States generic drugs market in the future five years.
Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sandoz US, Endo Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Abbott Laboratories Inc., Eli Lilly and Company, Sun Pharma Inc., Lupin Pharmaceuticals, Inc., and Zydus Pharmaceutical USA Inc. are among the major market players in the United States that lead the market growth of generic drugs.

Years considered for this report:

Historical Years: 2016-2019
Base Year: 2020
Estimated Year: 2021
Forecast Period: 2022-2026

Objective of the Study:

• To analyze the historical growth in the market size of United States generic drugs market from 2016 to 2020.
• To estimate and forecast the market size of United States generic drugs market from 2021 to 2026 and growth rate until 2026.
• To classify and forecast United States generic drugs market based on type, application, mode of drug delivery, form, source, distribution channel, competitional landscape, and regional distribution.
• To identify dominant region or segment in the United States generic drugs market.
• To identify drivers and challenges for United States generic drugs market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in United States generic drugs market.
• To identify and analyze the profile of leading players operating in United States generic drugs market.
• To identify key sustainable strategies adopted by market players in United States generic drugs market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the manufacturers which could not be identified due to the limitations of secondary research. The analyst examined the manufacturers, distribution channels and presence of all major players across the globe.
The analyst calculated the market size of the United States generic drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

• Generic drugs manufacturers, suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to generic drugs
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, United States generic drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• United States Generic Drugs Market, By Type:
o Small Molecule Generic
o Biosimilars
• United States Generic Drugs Market, By Application:
o Cardiovascular Diseases
o Diabetes
o Neurology
o Oncology
o Infectious Diseases
o Others
• United States Generic Drugs Market, By Mode of Drug Delivery:
o Oral
o Parenteral
o Topical
o Others
• United States Generic Drugs Market, By Form:
o Tablet
o Capsule
o Injection
o Others
• United States Generic Drugs, By Source:
o In House Manufacturing
o Contract Manufacturing Organizations
• United States Generic Drugs Market, By Distributions Channels:
o Retail Pharmacies
o Online Pharmacies
o Hospital Pharmacies
o Others
• United States Generic Drugs Market, By Region:
o South
o Midwest
o West
o Northeast

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global generic drugs market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06192577/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Yahoo Finance's Brad Smith reports on how PayPal stock is plunging after the company reported weaker-than-expected guidance.
Vaccine maker Novavax (NASDAQ: NVAX) has fallen harder than the broader market of late, dropping by 36% in the past three months alone. Meanwhile, Novavax's shares are trading at $95.22. Although Novavax's stock has been somewhat affected by factors outside of its control, the company also made several blunders of its own.
Glassdoor released its top job for 2022 based on earning potential, overall job satisfaction rating and number of job openings.
Shares of AbbVie Inc. gained 1.4% in premarket trading on Wednesday after the company beat earnings expectations and generated more sales than expected of its top-selling rheumatoid arthritis drug, Humira. AbbVie had earnings of $4.0 billion, or $2.26 per share, in the fourth quarter of 2021, compared with $36.0 million, or 1 cent per share, in the same quarter a year ago. Adjusted earnings per share were $3.31, against a FactSet consensus of $3.28. The company reported revenue of $14.8 billion
The company is making remarkable headway selling EVs and improving profits. Its quarterly results are due on Thursday.
The spinoff is part of AT&T’s planned deal to combine WarnerMedia with Discovery, a merger that is expected to close in the second quarter.
Moor Insights & Strategy CEO and Chief Analyst Patrick Moorhead joins Yahoo Finance Live to break down AMD's quarterly earnings and the outlook for chip shortages.
When it comes to biotechs, Moderna (NASDAQ: MRNA) is the standard to beat. On the surface, Inovio is very much in the same position that Moderna was before the pandemic. With a market cap close to $900 million, it doesn't have any recurring revenue or any medicines that are approved for sale, and its coronavirus vaccine program is what originally put it in the limelight in 2020.
Anavex Life Sciences on Tuesday touted the "very large" impact its treatment had on patients with Rett syndrome, but AVXL stock crashed.
(Bloomberg) — Alphabet Inc. announced a 20-for-1 stock split in the form of a one-time special stock dividend, aiming to draw a wider audience for its shares.Most Read from BloombergAlphabet Stock Split Aimed at Bringing Google Shares to MassesTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsSeaWorld Makes $3.4 Billion Takeover Bid for Cedar FairBe Warned — the Turbulence This Time Is DifferentCovid-Infected HIV Patient Developed Mutations, Study Shows“The reason f
(Bloomberg) — After falling out of favor, pot stocks including Canopy Growth Corp. and Tilray Brands Inc. are rebounding in a risk-on rally, with the renewed push to get cannabis legislation passed further helping fuel the rally. Most Read from BloombergTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsAlphabet Stock Split Aimed at Bringing Google Shares to MassesCovid-Infected HIV Patient Developed Mutations, Study ShowsSeaWorld Makes $3.4 Billion Takeover Bid for
Nvidia (NASDAQ: NVDA) share prices reached an all-time (split-adjusted) high of $346 in November after reporting another blockbuster quarter of earnings. In its fiscal 2022 third quarter (which ended Oct. 31), the graphics processing unit (GPU) specialist reported adjusted earnings growth of 60% year over year, driven by gains across its data center and gaming segments. The continued expansion of the data center industry will be key to that, since it's the company's fastest-growing and highest-margin business.
These three companies are each focusing on different segments of the EV market, but all three stocks have been hit by the 2022 correction.
Google-parent Alphabet reported Q4 earnings and revenue that topped estimates and announced a 20-for-1 stock split, sending Google stock up.
First – there are options for you to pay off your debt, and taking a lump sum from your retirement accounts should probably be the very last of them. Start by compiling a list of all of your debts, the exact balances, the interest rates they’re charging and if there are any other stipulations (such as a deadline to pay them before interest rates rise). Once you have that, you can see where the brunt of your debt is, and make a repayment plan.
Top digital payments stock PayPal is one of the leading growth stocks in the current stock market. But is it a buy right now?
Yahoo Finance's Julie Hyman and Brian Sozzi discuss the latest headlines moving AT&T and AMC stocks.
The investment options in your retirement plan may improve after the U.S. Supreme Court sided with Northwestern University employees who alleged the university’s retirement plans had excessively high fees and simply too many options. In a six-page opinion published last … Continue reading → The post How a New Supreme Court Decision Could Help You Save For Retirement appeared first on SmartAsset Blog.
Shares of Marathon Petroleum Corp shot up 3.9% toward a more-than three-year high after the oil refiner reported fourth-quarter profit that was more than double what was expected and also a big revenue beat, while also adding $5 billion to its stock buyback authorization. Net income shot up to $744 million, or $1.27 a share, from $285 million, or 44 cents a share, in the year-ago period, as the refining and marketing business swung to income of $881 million from a loss of $1.6 billion. Excluding
PayPal Holdings stock was sinking after the payments company reported earnings and guidance that fell short of Wall Street estimates. Shares of PayPal (ticker: PYPL) were tumbling 16.7% to $146.40 in premarket trading Wednesday after gaining 2.2% during regular trading hours on Tuesday. PayPal reported a fourth-quarter profit of $1.11 a share, missing forecasts for $1.12 a share, on sales of $6.92 billion, topping estimates for $6.89 billion.

source

Leave a Comment

Your email address will not be published.

Shopping Cart